Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (HK:6990) has released an update.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is moving forward with full circulation of its H shares, representing 0.52% of the company’s total share capital, pending necessary approvals and regulatory procedures. This strategic maneuver aims to enhance the liquidity of shares and is in line with guidelines set by the China Securities Regulatory Commission. Investors are advised to be cautious and stay tuned for further announcements regarding the progress of this initiative.
For further insights into HK:6990 stock, check out TipRanks’ Stock Analysis page.